Related references
Note: Only part of the references are listed.Efficacy and safety of glecaprevir/pibrentasvir in Japanese patients with chronic genotype 2 hepatitis C virus infection
Hidenori Toyoda et al.
HEPATOLOGY (2018)
Efficacy and safety of glecaprevir/pibrentasvir in Japanese patients with chronic genotype 1 hepatitis C virus infection with and without cirrhosis
Kazuaki Chayama et al.
JOURNAL OF GASTROENTEROLOGY (2018)
ENDURANCE-3: safety and efficacy of glecaprevir/pibrentasvir compared to sofosbuvir plus daclatasvir in treatment-naive HCV genotype 3-infected patients without cirrhosis
G. R. Foster et al.
JOURNAL OF HEPATOLOGY (2017)
MAGELLAN-1, Part 2: glecaprevir and pibrentasvir for 12 or 16 weeks in patients with chronic hepatitis C virus genotype 1 or 4 and prior direct-acting antiviral treatment failure
F. Poordad et al.
JOURNAL OF HEPATOLOGY (2017)
In Vitro Antiviral Activity and Resistance Profile of the Next-Generation Hepatitis C Virus NS5A Inhibitor Pibrentasvir
Teresa I. Ng et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2017)
Complex Pattern of Resistance-Associated Substitutions of Hepatitis C Virus after Daclatasvir/Asunaprevir Treatment Failure
Jun Itakura et al.
PLoS One (2016)
Randomized phase 3 trial of ombitasvir/paritaprevir/ritonavir for hepatitis C virus genotype 1b-infected Japanese patients with or without cirrhosis
Hiromitsu Kumada et al.
HEPATOLOGY (2015)
A review of the burden of hepatitis C virus infection in China, Japan, South Korea and Taiwan
Heather Bennett et al.
HEPATOLOGY INTERNATIONAL (2015)
Ledipasvir and sofosbuvir fixed-dose combination with and without ribavirin for 12 weeks in treatment-naive and previously treated Japanese patients with genotype 1 hepatitis C: an open-label, randomised, phase 3 trial
Masashi Mizokami et al.
LANCET INFECTIOUS DISEASES (2015)
Sofosbuvir plus ribavirin in Japanese patients with chronic genotype 2 HCV infection: an open-label, phase 3 trial
Masao Omata et al.
JOURNAL OF VIRAL HEPATITIS (2014)
Sofosbuvir and Ribavirin in HCV Genotypes 2 and 3
Stefan Zeuzem et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Global epidemiology of hepatitis C virus infection: New estimates of age-specific antibody to HCV seroprevalence
Khayriyyah Mohd Hanafiah et al.
HEPATOLOGY (2013)
Resistance Analysis of Hepatitis C Virus Genotype 1 Prior Treatment Null Responders Receiving Daclatasvir and Asunaprevir
Fiona McPhee et al.
HEPATOLOGY (2013)
Response-Guided Peg-Interferon Plus Ribavirin Treatment Duration in Chronic Hepatitis C: Meta-Analyses of Randomized, Controlled Trials and Implications for the Future
Vincent Di Martino et al.
HEPATOLOGY (2011)
A systematic review of hepatitis C virus epidemiology in Asia, Australia and Egypt
William Sievert et al.
LIVER INTERNATIONAL (2011)
Treatment of chronic hepatitis C in Asia: When East meets West
Ming-Lung Yu et al.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY (2009)
Epidemiology of hepatitis C: Geographic differences and temporal trends
A Wasley et al.
SEMINARS IN LIVER DISEASE (2000)
Share Paper
